🇺🇸 FDA
Patent

US 8937055

Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action

granted A61KA61K31/4418A61K31/4439

Quick answer

US patent 8937055 (Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action) held by Takeda Pharmaceutical Company Limited expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jan 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/4418, A61K31/4439, A61K31/506, A61K31/5377